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The role of anticoagulant agents in managing patients with
acute myocardial infarction (MI) has long been controversial.
The first clinical trials evaluating anticoagulation for acute MI
were published in 1948, and by 1969 the results of some 32
studies involving .12,000 patients had been published (1). In
analyzing these studies, Gifford and Feinstein (1) suggested
that serious methodologic limitations in the majority of the
trials precluded drawing any firm conclusions about the efficacy
of anticoagulant therapy.
In 1977, Chalmers et al. (2) again reviewed the studies
reported by Gifford and Feinstein (1) and added data from
four randomized trials published subsequent to the original
analysis. Based primarily on pooled data from six randomized
trials involving 3,854 patients, Chalmers et al. (2) concluded
that “all patients who present no specific contraindication
should receive anticoagulants during hospitalization for infarc-
tion.” In retrospect, this conclusion is a bit surprising because
there was considerable variability in the design of these trials as
well as in the therapeutic regimen utilized. In particular, only
the two smallest studies, involving a total of 145 subjects,
compared heparin with placebo. In the other studies, oral
anticoagulation (phenitidione or warfarin), alone or in combi-
nation with intravenous or subcutaneous heparin boluses, was
compared with placebo or “low dose” anticoagulation. From
the perspective of current practice, an even greater limitation
of these trials is that none of the patients were treated with
aspirin.
In the late 1970s, studies by DeWood et al. (3) and others
provided compelling evidence that in situ coronary thrombosis
plays a critical role in the pathogenesis of acute MI, and these
observations led to intensive investigation of the use of anti-
platelet, antithrombotic and fibrinolytic agents in patients with
acute coronary ischemia. Some 20 years and an untold number
of studies later, we now know that antiplatelet therapy with
relatively low doses of aspirin provides substantial benefits
across the full spectrum of unstable coronary syndromes, and
that fibrinolytic therapy dramatically reduces infarct size and
mortality in the subgroup of patients with “transmural” MI.
However, the role of antithrombotic therapy in the early stages
of MI management, both in patients who are treated with a
thrombolytic agent and those who are not, remains uncertain
(4–6). The key issue here is not whether early anticoagulation
with heparin is superior to placebo in improving MI outcomes
(available data suggest that it is), but whether heparin provides
additional benefit compared with aspirin alone. In the present
context, it is worth pointing out that the potential benefit of
heparin is not limited to its effect on mortality, but may include
reductions in reinfarctions as well as a host of thromboembolic
complications, both venous and arterial. Conversely, any ben-
efits must be weighed against the risk of serious bleeding,
including intracranial hemorrhage.
Several recent studies, including Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-2)
(7), Third International Study of Infarct Survival (ISIS-3) (8)
and Global Utilization of Streptokinase and TPA for Occluded
Coronary Arteries (GUSTO-1) (9), have provided insight into
the use of heparin in patients with an acute MI treated with a
thrombolytic agent. In contrast, there have been no published
placebo-controlled trials of early anticoagulation in patients
with acute MI treated with aspirin but not receiving a throm-
bolytic agent. Indeed, the lack of data regarding the use of
heparin in this large (60% to 70% of all MIs in the United
States) and rather heterogeneous subgroup has resulted in
rather ambiguous recommendations from both the American
College of Chest Physicians (ACCP) and the American Col-
lege of Cardiology/American Heart Association (ACC/AHA)
Task Force (10,11). Whereas both groups strongly recommend
that high risk patients, including those with a large anterior MI,
severe left ventricular dysfunction, atrial fibrillation or a his-
tory of systemic or pulmonary embolism, be treated with
full-dose intravenous heparin, the ACCP suggests that other
patients should receive “not less than low-dose heparin therapy
(7,500 U subcutaneously every 12 hours)” (10). Similarly, the
ACC/AHA Task Force (11) considers the indications for
heparin as class IIa and suggests that heparin be given “sub-
cutaneously (7500 U twice daily) (intravenous heparin is an
acceptable alternative) in all patients not treated with throm-
bolytic therapy who do not have a contraindication to hepa-
rin.” In discussing this issue, the authors of the Task Force
Guidelines note that “in patients who will not be given
thrombolytic therapy, there is little evidence about the benefit
of heparin in the modern era” (11).
To summarize, currently available data on the use of
heparin in patients with an acute MI is inconclusive, and this
applies particularly to patients not receiving thrombolytic
therapy. Nonetheless, full-dose intravenous heparin is admin-
istered to the majority of patients admitted to the hospital with
acute MI in the U.S. (12), presumably because most cardiolo-
gists believe that it is likely to have a beneficial effect either
directly (i.e., at the site of coronary thrombosis), or indirectly,
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through the prevention of other thromboembolic complica-
tions.
Myocardial infarction in the elderly. In 1994, there were
759,000 hospital admissions in the United States with a first-
listed discharge diagnosis of acute MI (13). Of these, 59.6%
occurred in patients .65 years old (13). Moreover, patients
.65 years old account for five of every six hospital deaths from
acute MI, and three of every five deaths occur in patients .75
years old (14,15). Thus, although people .65 comprise only
13% of the U.S. population, they account for well over half of
all MIs, and the case-fatality rate in this population is ex-
tremely high. Furthermore, the proportion of MI patients .65
years old is likely to increase in the decades ahead due to the
aging of the population as well as a rightward shift in the age
at onset of first coronary events resulting from continued
advances in risk factor modification and primary prevention.
For these reasons, there is an urgent need to identify thera-
peutic strategies that are beneficial in older patients and to
clarify subgroups of patients who benefit from specific inter-
ventions.
One implication of the high acute MI fatality rate in the
elderly is that the absolute potential for improving outcomes is
greater in older MI patients than in younger ones, simply
because event rates are much higher in the elderly. Indeed,
recent studies indicate that the beneficial effects of aspirin,
beta-adrenergic blocking agents, angiotensin-converting en-
zyme inhibitors and fibrinolytic agents are at least as great in
the elderly as in younger patients (16). Unfortunately, the
converse is also true; that is, older patients are at higher risk
for adverse consequences when treated with agents that are
lacking in benefit.
These considerations are particularly germane to the use of
heparin. If heparin is indeed beneficial, then older patients
might be expected to reap the greatest benefits. If, on the other
hand, heparin is not beneficial, bleeding complications, hem-
orrhagic strokes and possibly heparin-induced thrombocytope-
nia may be more prone to occur in older patients. The problem
is that no prospective, randomized trials of heparin versus no
heparin have been conducted in the modern era in patients not
receiving fibrinolytic therapy; therefore, we must rely on
alternative data sources to aid in clinical decision making.
The current study. In this issue of the Journal, Krumholz et
al. (17) describe the results of a retrospective cohort study
involving 6,935 patients $65 years old admitted to the hospital
with an acute MI from June 1992 to February 1993 in one of
four states. Medical records data were analyzed to determine
the frequency of full-dose intravenous heparin utilization in
patients not undergoing reperfusion therapy. Patients were
excluded from the analysis if they had a contraindication to
heparin or a noncardiac terminal illness. The average age of
the study population was 76 years, and 52% were male.
Overall, 47% of the study population received full-dose
intravenous heparin within the first 2 days of hospital admis-
sion. This proportion is similar to that reported by Weaver et
al. (18) in the Myocardial Infarction Triage and Intervention
(MITI) project (48% among 1,842 patients $65 years old) and
by the National Registry of Myocardial Infarction (NRMI)
investigators (56% among patients not receiving thrombolytic
therapy) (12). As evidence that the dose of heparin used was
effective in achieving an appropriate level of anticoagulation,
the authors reported that 88% of patients given heparin had a
documented activated partial thromboplastin time .46 s
within the first 24 h of initiation of therapy.
The unadjusted 30-day mortality rate in patients receiving
heparin was 13.4% compared with 18.6% in patients not
receiving heparin (odds ratio 0.67, p , 0.001). However, there
were substantial baseline demographic and clinical differences
between the heparin and nonheparin groups, such that the
heparin-treated patients comprised a relatively low risk sub-
group of the total population. In addition, the use of “proven”
MI therapies, including aspirin and beta-blockers, occurred
more frequently in the heparin cohort. To adjust for these
differences, the authors performed a series of multivariable
logistic regressions and found that these baseline differences
accounted for all apparent mortality differences between
groups. Thus, in the final model the odds ratio for 30-day
mortality was 1.02 (95% confidence interval 0.87 to 1.18) for
heparin-treated versus nonheparin-treated patients. Further-
more, multiple subgroup analyses based on age, presence of
diabetes or heart failure, previous MI and aspirin use failed to
identify any subgroup that appeared to benefit from intrave-
nous heparin.
In contrast to the “negative” findings with respect to
mortality, heparin-treated patients experienced a twofold
greater incidence of major hemorrhage and need for transfu-
sion. The number of strokes was also higher in the heparin
group, although not significantly so, and in a restricted cohort
of the study sample, heparin-treated patients had an increased
length of hospital stay compared with nonheparin-treated
patients (10.6 vs. 9.3 days, p , 0.001; Krumholz HM, personal
communication, 1997). This difference, which persisted after
adjustment for baseline demographic and clinical factors, may
reflect the increased incidence of bleeding complications that
occurred in the heparin group.
The authors concluded that in this large cohort of older MI
patients not undergoing reperfusion therapy, there was no
evidence of a significant mortality benefit attributable to
intravenous heparin (17).
Strengths and limitations. Because of the study’s large
sample size, meticulous data collection by experienced chart
reviewers and sophisticated statistical analysis, the findings are
quite robust, and it is unlikely that even a small benefit
attributable to heparin was missed (type II error). In addition,
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because the data are representative of practice patterns at all
acute care hospitals in four states, the study avoids the
selection bias that may occur in studies confined to academic
or other referral centers.
As the authors point out, the major limitation of their study
is the lack of random allocation of heparin therapy. In addi-
tion, data were collected retrospectively by chart review, and
there is thus no way to verify the accuracy of the data. It is
possible, for example, that major bleeding episodes were
documented more consistently in patients receiving heparin, or
that heparin-treated patients were more likely to undergo
cardiac catheterization and angioplasty, both of which could
increase the risk of bleeding unrelated to heparin therapy.
Similarly, these additional procedures could have contributed
to the increased length of stay in the heparin cohort. Also, no
data are provided on the incidence of nonfatal thromboem-
bolic complications, which may occur less frequently in
heparin-treated patients (10,11). Finally, the fact that data
were collected 5 years ago may represent an additional limita-
tion because the current, more prevalent use of weight-based
heparin dosing nomograms may result in greater efficacy and
fewer bleeding complications (19,20).
Clinical implications. Despite these limitations, the results
of the present study, which are generally concordant with
previous reports, provide additional evidence that routine
heparinization is unlikely to favorably influence mortality in
patients with an MI receiving standard therapy with aspirin.
Moreover, as in virtually all previous studies, the incidence of
major bleeding complications is increased in patients treated
with heparin. These findings clearly suggest that the risk-
benefit ratio of full-dose intravenous heparin may be unfavor-
able, particularly in the large cohort of older patients not
undergoing primary reperfusion therapy. Therefore, routine
use of intravenous heparin in these patients cannot be recom-
mended at this time. However, the findings of this study do not
negate the value of heparin in selected patients with well
defined indications for its use, as outlined in the ACCP and
ACC/AHA guidelines (10,11).
The future. Clearly, the only way to resolve the heparin
debate is to conduct a prospective, randomized trial of sufficient
size to detect clinically meaningful differences in outcomes.
Alternatively, conventional antithrombotic therapy with heparin
may be rendered obsolete by newer agents, such as the low
molecular weight heparins and glycoprotein IIb/IIIa inhibitors
(21,22). Large randomized trials evaluating these classes of drugs
are currently underway, but it may be several years before the
results of these studies are available. In the meantime, it seems
likely that the heparin controversy will continue unabated.
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